M6A modification is crucial for HIV-1 survival
The discovery of three m6A modifications and their exact locations could lead to the development of drugs that inhibit viral RNA and protein production.
List view / Grid view
News
FOXO1 improves survival and function of CAR T cells
Evidence indicating that FOXO1 plays a unique role in promoting T cell longevity could result in more effective CAR T cell therapies.
Proteogenomic signatures: metastatic prostate cancer risk
Mutation signatures and recurrent copy number alterations correlated with a higher risk for disease progression.
Elevated TMAO levels predict future risk of CKD
Elevated levels of trimethylamine N-oxide levels were a stronger indicator of CKD risk than the well-known risk factors.
Link identified between bacteria and cancer treatment efficacy
Researchers mapped the bacteria present in over 4000 metastatic tumour biopsies, which could enable the exploration of new treatments.
B-ALL: combination therapy effectively controls high-risk subtypes
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
KCNJ2 inhibition: a therapeutic target for traumatic brain injury
Using cortical organoids, researchers discovered that targeting KCNJ2 could reduce nerve cell death after TBI.
Atlas of the human ovary offers huge potential for new treatments
Single-cell RNA sequencing of ovaries resulted in the identification of four major cell types and four immune cell subtypes.
Investigating new treatments for polycystic kidney disease
Organoid models enabled the researchers to study the effectiveness of eukaryotic ribosomal selective glycoside drugs on PKD cyst formation.
Exploring the effects of IFNβ in neuroHIV infection
IFNβ could be developed into a new therapy, following an improved understanding of how innate immunity affects the brain during chronic HIV infection.
Rare genetic variants found to have a large impact on obesity risk
Researchers have gained a deeper understanding of the neural biology of obesity, which could offer potential drug targets.
Exploring the conditions in which pathological 4R tau misfolds
Researchers have presented new findings that offer potential pathways to arrest critical steps toward the accumulation of mutant tau.
New treatment for metabolic dysfunction-associated steatohepatitis
The compound 11c demonstrates an excellent safety profile and is an exciting advancement in liver disease management.
Combatting T-cell tumours with antibody drug conjugates
One treatment with the anti-TRBC1-SG3249 ADC combination saw cancer elimination within seven days in mouse models.
Reversing malignant cancer cells to a normal state
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.